**Case Report**

Granulomatosis with polyangiitis following Pfizer-BioNTech COVID-19 vaccination

**Running Title:** GPA following COVID-19 vaccination

Tsuyoshi Shirai¹, Jun Suzuki², Shimpei Kuniyoshi³, Yuito Tanno¹, Hiroshi Fujii¹

¹Department of Rheumatology, Tohoku University Hospital, Miyagi, Japan
²Department of Otolaryngology, Head and Neck Surgery, Tohoku University Graduate School of Medicine, Miyagi, Japan
³Department of Pathology, Tohoku University Graduate School of Medicine, Miyagi, Japan

**Corresponding author:** Tsuyoshi Shirai,
Department of Rheumatology, Tohoku University Hospital,
1-1 Seiryo-machi, Aoba-ku, Sendai, 980-8574, Japan
Tel: 81-22-717-7165, Fax: 81-22-717-7497, E-mail: tsuyoshirajp@med.tohoku.ac.jp

Key words : ANCA, COVID-19, granulomatosis with polyangiitis, otitis media, vaccination

**Abstract**

We report the first case of proteinase 3 (PR3)-antineutrophil cytoplasmic antibody (ANCA)-positive granulomatosis with polyangiitis (GPA) with predominant ears, nose, and throat (ENT) manifestations following COVID-19 vaccination. A 63-year-old woman presented with aural fullness three days after vaccination. She presented with progressive rhinosinusitis and otitis media leading to profound hearing loss within three weeks. Clinical imaging revealed soft-tissue shadows in the paranasal sinuses with multiple pulmonary nodules, and histopathology was consistent with a diagnosis of GPA. It is crucial to be wary of the possibility of GPA in patients who received COVID-19 vaccines due to its rapid disease progression.
Background

The coronavirus disease 2019 (COVID-19) pandemic has significantly influenced our lives. Vaccination is one of the cornerstones critical to control COVID-19. The safety and efficacy of COVID-19 vaccines have been globally accepted. However, cases of autoimmune diseases including giant cell arteritis following COVID-19 vaccination have been described (1, 2). Among antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAVs), granulomatosis with polyangiitis (GPA) presents with characteristic symptoms in the ears, nose, and throat (ENT). To the best of our knowledge, only two cases of AAV following COVID-19 vaccination have been described, presenting with necrotizing glomerulonephritis (3, 4). Here, we report the first case of proteinase 3 (PR3)-ANCA-positive GPA with predominant ENT manifestations following COVID-19 vaccination (Pfizer-BioNTech).

Case Report

An otherwise healthy 63-year-old woman was admitted to our hospital for severe vertigo and hearing loss 22 days after receiving the first dose of Pfizer-BioNTech COVID-19 vaccine. She underwent a medical checkup three months ago, and her chest X-ray was normal at that time. Three days after vaccination, she presented with mild fever, right aural fullness, and bilateral nasal congestion. She was diagnosed with rhinosinusitis and otitis media. However, treatment with antibiotics for two weeks did not improve her condition. On the day of admission, she experienced severe vertigo and headache, which prompted consult to the previous hospital. Magnetic resonance imaging showed edematous thickening of the maxillary sinus and mastoid cells (Figure 1A). Computed tomography (CT) revealed soft-tissue shadows in the paranasal sinuses with multiple pulmonary nodules (Figure 1B), consistent with the previous diagnosis of right otitis media, mastoiditis, and maxillary sinusitis. However, based on these findings, GPA was suspected, which prompted a referral to our hospital for further evaluation.

On admission, the patient was conscious with a slightly elevated body temperature (37.1 °C). Otolaryngologic examination revealed unidirectional horizontal spontaneous nystagmus to the left and bulging tympanic membrane with purulent effusion in the right ear (Figure 1C). Rhinoscopy showed bilateral nasal mucosal swelling and erosion (Figure 1D). Pulmonary examination was unremarkable.

Blood tests showed elevated white cell count (12 800 cells/µL). Laboratory examinations revealed
increased C-reactive protein levels (14.32 mg/dL) and normal renal function. Urinalysis was unremarkable. Serologic tests demonstrated elevated PR3-ANCA levels (259 U/mL; normal, <3.5 U/mL) with negative MPO-ANCA. Pure tone audiometry revealed right profound hearing loss with bone conduction threshold deterioration. Histopathologic examination of the nasal mucosa revealed fibrin deposition in the small vessels and granulation tissue with intensive infiltration of inflammatory cells, predominantly neutrophils (Figure 1E). These findings were consistent with a diagnosis of GPA. Although evaluations for lung nodules were planned, vertigo worsened severely the day after admission, with high fever and elevation of inflammatory markers, which prompted us to initiate immunosuppression. Because of concerns of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection after the use of rituximab, she was treated with prednisolone (60 mg/day) and intravenous cyclophosphamide (500mg), which improved her conditions. The follow-up CT revealed regression of lung nodules, supporting the idea that they were inflammatory in nature.

Discussion
Six cases of AAV following COVID-19 have been described previously (5). All patients were diagnosed with necrotizing glomerulonephritis, and the positivity for MPO-ANCA and PR3-ANCA was half and half. Moreover, two cases of AAV after COVID-19 vaccination have been reported, presenting with glomerulonephritis. The first patient experienced PR3-ANCA-positive glomerulonephritis following inoculation with Moderna vaccine (3). In contrast, the second case was diagnosed with MPO-ANCA-positive crescentic necrotizing glomerulonephritis after Pfizer-BioNTech COVID-19 vaccination (4). Cases of AAV have also been reported following influenza vaccinations (6). Although drug-induced AAV is usually associated with MPO-ANCA, no predilection for ANCA type exists in AAV associated with SARS-CoV-2 infection and vaccination.

Unlike other cases, our patient presented with progressive rhinosinusitis and otitis media leading to profound hearing loss within three weeks. The presence of hearing loss with bone conduction threshold deterioration and vertigo with unidirectional spontaneous nystagmus suggested severe inner ear damage. Moreover, the presence of pulmonary nodules indicated the systemic progression of GPA. Although PR3-ANCA-positive GPA is less common in Japan, this study described a case of PR3-ANCA-positive GPA three days after COVID-19 vaccination (Pfizer-BioNTech) in a Japanese patient presenting with typical upper and lower respiratory manifestations. Although it is difficult to
demonstrate a causal relationship between COVID-19 vaccination and GPA, it is crucial to be wary of the possibility of GPA in patients who received COVID-19 vaccines due to its rapid disease progression. It is not certain whether spontaneous improvement could be expected in AAVs following vaccination, and appropriate treatments should be performed without delay.

Development of AAVs has been observed after both SARS-CoV-2 infection and vaccination (3-5). This evidence suggests that the immune response against SARS-CoV-2, mRNA vaccines, and adjuvants could trigger the onset of AAVs, especially in individuals that have a predisposition to AAVs. Since it is possible that patients who developed AAVs following COVID-19 vaccination are also at high risk for developing AAVs following SARS-CoV-2 infection, the benefits of COVID-19 vaccination would outweigh the risks in the era of the pandemic. On the other hand, re-administration of a vaccine should be carefully considered in such cases. This study highlights the importance of evaluating patients for ENT symptoms after COVID-19 vaccination.

Financial Disclosure

This work was supported by JSPS KAKENHI (Grant Number: 21K08469) for TS.

Conflict of Interest

None.

Ethics Approval

This work was approved by Ethics committee of the Tohoku University Graduate School of Medicine (Approval number, 23185).

Patient Consent

Written informed consent for the publication of this case report was obtained from the patient.

Acknowledgments

The authors thank the staff of the Department of Hematology & Rheumatology, Tohoku University, for their helpful inputs.
References

1. Curtis JR, Johnson SR, Anthony DD, Arasaratnam RJ, Baden LR, Bass AR et al. American College of Rheumatology Guidance for COVID-19 Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: Version 1. Arthritis Rheumatol 2021;73:1093-107.

2. Mejren A, Sorensen CM, Gormsen LC, Tougaard RS, Nielsen BD. Large-vessel giant cell arteritis after COVID-19 vaccine. Scand J Rheumatol 2021:1-2.

3. Sekar A, Campbell R, Tabbara J, Rastogi P. ANCA glomerulonephritis after the Moderna COVID-19 vaccination. Kidney Int 2021;100:473-4.

4. Shakoor MT, Birkenbach MP, Lynch M. ANCA-Associated Vasculitis Following Pfizer-BioNTech COVID-19 Vaccine. Am J Kidney Dis 2021;78:611-3.

5. Izci Duran T, Turkmen E, Dilek M, Sayarlioglu H, Arik N. ANCA-associated vasculitis after COVID-19. Rheumatol Int 2021;41:1523-9.

6. Watanabe T. Vasculitis Following Influenza Vaccination: A Review of the Literature. Curr Rheumatol Rev 2017;13:188-96.

Figure legend

Figure 1. Imaging, clinical, and histopathologic findings.

A. Magnetic resonance imaging shows edematous thickening of the maxillary sinus (yellow arrows) and mastoid cells (white arrows). B. Computed tomography reveals soft-tissue shadows in the paranasal sinuses (yellow arrows) and multiple nodules in the lungs (white arrows). C. Otoscopy demonstrates a bulging tympanic membrane with purulent effusion in the right ear. D. Rhinoscopy shows swelling and erosion of the bilateral nasal mucosa. E. Histopathologic examination of the nasal mucosa reveals vascular fibrin deposition (yellow arrows) and granulation tissue with intensive infiltration of inflammatory cells, predominantly neutrophils. Black bar indicates 50 μm.
